Assurance Report on the Deposit, Management, and Actual Use of Raised Funds for 2025
To the Shareholders of Tianjin Anji Medical Electronic Co., Ltd.:
We have audited the attached 2025 Annual Report on the Deposit, Management, and Actual Use of Raised Funds (the "Special Report") prepared by the Board of Directors of Tianjin Anji Medical Electronic Co., Ltd. (hereinafter referred to as "Anji Medical Company").
I. Limitation on Users and Purpose of the Report
This assurance report is intended solely for the purpose of disclosure in Anji Medical Company's annual report and shall not be used for any other purpose. We agree that this assurance report shall be an essential document of Anji Medical Company's annual report and shall be submitted and disclosed externally along with other documents.
II. Responsibilities of the Board of Directors
In accordance with the "Supervision Measures for Raised Funds of Listed Companies" issued by the China Securities Regulatory Commission, the "Shenzhen Stock Exchange Main Board Listed Company Standardized Operation Guide No. 1," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 2 - Announcement Format," the preparation of the "Special Report on the Deposit, Management, and Actual Use of Raised Funds for the Year" is the responsibility of the Board of Directors of Anji Medical Company. This responsibility includes ensuring that the content is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
III. Responsibilities of the Registered Public Accountants
Our responsibility is to independently express an assurance conclusion on the aforementioned report prepared by the Board of Directors of Anji Medical Company.
IV. Overview of Work
We performed the assurance engagement in accordance with the "Other Assurance Services Practice Standards for Chinese Certified Public Accountants No. 3101 - Assurance Engagements Other Than Audits or Reviews of Historical Financial Information." This standard requires us to plan and perform the assurance engagement to obtain reasonable assurance about whether the information subject to assurance is free from material misstatement. In the course of the assurance engagement, we performed procedures, including the examination of accounting records, that we considered necessary. We believe that our assurance work provides a reasonable basis for expressing our opinion.
V. Assurance Conclusion
We are of the opinion that the attached 2025 "Special Report on the Deposit, Management, and Actual Use of Raised Funds" of Anji Medical Company has been prepared, in all material respects, in accordance with the aforementioned "Supervision Measures for Raised Funds of Listed Companies" and the relevant regulations of the stock exchange, and fairly reflects the actual situation of the deposit, management, and use of raised funds of Anji Medical Company for the year 2025.
(This page is the signature and seal page for the Assurance Report on the Deposit, Management, and Actual Use of Raised Funds for 2025, RSM Special Letter No. [2026]100Z1205, of Anji Medical Company.)
RSM Accounting Firm (Special General Partnership) China Certified Public Accountant: Zhang Hongyan China·Beijing China Certified Public Accountant: Wang Zhun 2026 April 28
Tianjin Anji Medical Electronic Co., Ltd.
Special Report on the Deposit, Management, and Actual Use of Raised Funds for the Year
In accordance with the "Supervision Measures for Raised Funds of Listed Companies" issued by the China Securities Regulatory Commission, the "Shenzhen Stock Exchange Main Board Listed Company Standardized Operation Guide No. 1," and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Supervision Guidelines No. 2 - Announcement Format," the report on the deposit, management, and use of raised funds by Tianjin Anji Medical Electronic Co., Ltd. (hereinafter referred to as the "Company") for the year 2025 is as follows: